• Stephen C B Lim, Michael J Paech, Bruce Sunderland, and Yandi Liu.
• Pharmacy Department, Armadale Health Service, Armadale, Australia. stephen.lim@health.wa.gov.au
• Drug Des Dev Ther. 2013 Jan 1;7:317-24.

BackgroundThe objective of this study was to prepare a novel fentanyl wafer formulation by a freeze-drying method, and to evaluate its in vitro and in vivo release characteristics, including its bioavailability via the sublingual route.MethodsThe wafer formulation was prepared by freeze-drying an aqueous dispersion of fentanyl containing sodium carboxymethylcellulose and amylogum as matrix formers. Uniformity of weight, friability, and dissolution testing of the fentanyl wafer was achieved using standard methods, and the residual moisture content was measured. The fentanyl wafer was also examined using scanning electron microscopy and x-ray diffraction. The absolute bioavailability of the fentanyl wafer was evaluated in 11 opioid-naïve adult female patients using a randomized crossover design.ResultsIn vitro release showed that almost 90% of the fentanyl dissolved in one minute. In vivo, the first detectable plasma fentanyl concentration was observed after 3.5 minutes and the peak plasma concentration between 61.5 and 67 minutes. The median absolute bioavailability was 53.0%.ConclusionThese results indicate that this wafer has potential as an alternative sublingual fentanyl formulation.

32 keywords...

hide…